Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex for reversal of neuromuscular blockade in pediatric patients
2017-000692-92Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2018
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Sugammadex in neuromuscular block (NMB) (3 arms), sponsored by Merck & Co. Primary endpoint: Pharmacokinetic parameters of sugammadex. Started Sep 2018; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular block (NMB)
Beyond the preview
Go deeper on 2017-000692-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000692-92.